ZSAN Zosano Pharma Corporation

0.93
-0.04  -4%
Previous Close 0.97
Open 0.97
Price To book 1.66
Market Cap 36472221
Shares 39,230,097
Volume 306,388
Short Ratio 7.70
Av. Daily Volume 542,539

SEC filingsSee all SEC filings

  1. 8-K - Current report 171047647
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171021864
  3. 8-K - Current report 171021658
  4. 8-K - Current report 17902956
  5. S-8 - Securities to be offered to employees in employee benefit plans 17891595

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial data due released February 13, 2017 - primary endpoints met.
M207
Migraine
Phase 2 data released September 2015. Considering Phase 3 initiation in 2016
ZP-Glucagon
Severe hypoglycemia

SEC Filings

  1. 8-K - Current report 171047647
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171021864
  3. 8-K - Current report 171021658
  4. 8-K - Current report 17902956
  5. S-8 - Securities to be offered to employees in employee benefit plans 17891595
  6. 8-K - Current report 17891518
  7. 8-K/A [Amend] - Current report 17866783
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 17827477
  9. 8-K - Current report 17826382
  10. 8-K - Current report 17819553